Introduction
The development of resistance to chemotherapy represents an adaptive biological response by tumor cells that leads to treatment failure and patient relapse. In recent years, the mechanisms by which cancer cells become chemoresistant have attracted particular interest because this phenomenon concerns not only classical cytotoxic drugs but also newly developed agents against specific targets such as protein kinases (Roumiantsev et al., 2002; Shannon, 2002) . During the course of their evolution (intrinsic resistance) or in response to chemotherapy (acquired resistance), tumor cells may undergo genetic alterations to possess a drug-resistant phenotype. Dysregulation of membrane transport proteins and cellular enzymes (Gottesman et al., 1995) , drug targets (Gorre et al., 2001) , and altered susceptibility to commit apoptosis (Schmitt et al., 1997; Fulda and Debatin, 2003; Debatin and Krammer, 2004) are among the mechanisms believed to contribute to the genesis of acquired drug resistance. Activation of survival pathways such as those mediated by Akt and Stat3 has been also demonstrated to exert protective effects against stress-induced cell death and thus, thought to participate in the development of drug resistance in cancer (Dalton and Jove, 1999; Rebbaa et al., 2001; West et al., 2002; Pommier et al., 2004) .
Although numerous studies have been performed to understand the mechanisms of acquired drug resistance, putative crosstalk between drug-resistant cells and neighboring sensitive ones has not yet been described. In order for a drug-resistant tumor to subsist, not only cells with acquired drug resistance but also surrounding tumoral and nontumoral drug-sensitive cells within the tumor mass must survive. Thus, the concept of a cytoprotective relationship between drug-resistant andsensitive cells within such tumors seems rational. We proposed that tumor cells with acquired resistance to chemotherapy may secrete survival molecules able to initiate protective mechanisms in neighboring drugsensitive cells. Previous studies from this laboratory have shown that culture medium (CM) from doxorubicin-resistant human neuroblastoma cells (SKN-SH/ R) protected drug-sensitive cells from drug toxicity (Rebbaa et al., 2001 ). The signaling pathways by which CM elicits its cytoprotective action appeared to involve increased Stat3 and Akt activation as well as inhibition of caspase-3 activation (Rebbaa et al., 2001; Emran et al., 2002) . In the present study, a cytokine cDNA array was utilized to identify putative survival molecules and midkine emerged as a lead candidate responsible for mediating the cytoprotective effect of CM from drugresistant cells against doxorubicin toxicity in drugsensitive cells. This molecule appeared to act through activation of the survival pathway mediated by Akt and by inhibiting irreversible growth arrest (also called senescence) caused by doxorubicin.
Results

Coculture of drug-sensitive and -resistant cells protects the sensitive cells from drug toxicity and inhibits caspase-3 activation
We have shown previously that CM from doxorubicin resistant cells exerts a protective effect on their parental cell line against drug toxicity (Rebbaa et al., 2001) and that activation of both Stat3 and Akt survival pathways appeared to mediate this effect (Emran et al., 2002) . To better understand this cytoprotective relationship, we used a coculture system in which the sensitive cells were transfected with the fluorescent protein GFP. The labeled cells have retained their original sensitivity to doxorubicin (data not shown); however, when cocultured with nonfluorescent resistant cells and treated with doxorubicin, the number of fluorescent cells per defined area was higher (Po0.001) as compared to drug-sensitive cells alone (Figure 1a and b) . At a concentration of 1 mM doxorubicin, caspase-3 was strongly activated in wild-type cells, while only traces of its active form were detected in resistant cells (Rebbaa et al., 2001 and Figure 1c) . We have taken advantage of this fact to determine the effect of cellular cocultures on activation of caspase-3 in wild-type cells at this specific drug concentration. Cells were coincubated at the indicated ratios for 48 h after which doxorubicin was added and caspase-3 activation was measured by Western blot 24 h later using a specific antibody for cleaved (activated) caspase-3. As shown in Figure 1c , doxorubicin induced a very strong activation of caspase-3 in wild-type as compared to doxorubicin-resistant cells, interestingly, coculture of the two cell lines led to reduced enzyme activation in a manner that correlated with increased ratios of resistant cells. These findings suggested that the secreted factors from drug-resistant cells may have antiapoptotic activity.
Identification of the secreted antiapoptotic factors by cytokine cDNA array
Bolstered by the likelihood that these molecules were members of the cytokine family of growth factors, as they activated Stat3 and Akt (Johnson, 1998; Hirano et al., 2000; Klein et al., 2003) , we employed a cytokine cDNA array to identify putative differences in their expression. The array contains about 268 genes representing various cytokines, chemokines, and growth factors spotted on a nitrocellulose membrane. This technique, utilizing RNA extracted from In order to load the same amount of proteins from WT cells in each lane, 50 mg of proteins were loaded in the first 4 lanes from the left, 75 mg in lane 5, 100 mg in lane 6 and 150 mg in lane 7. Activation of caspase-3 was measured by Western blot using a specific antibody against the cleaved enzyme. Antibody against b-Actin was used as a loading control doxorubicin-sensitive and -resistant SKN-SH cells, revealed only minor differential expression for several molecules, however, one cytokine, identified as midkine, was highly expressed in drug-resistant cells and almost absent in their sensitive counterparts (Figure 2a ). This molecule has been shown to play a role in cell survival (Satoh et al., 1993; Unoki et al., 1994; Masuda et al., 1995) and high concentrations of midkine were associated with poor prognosis in tumors such as neuroblastoma . The molecular mechanisms underlying the survival function of midkine are not fully understood; however, current findings point to an antiapoptotic role for this molecule. For instance, midkine was found to rescue Wilms' tumor cells from cisplatin-induced apoptosis through enhanced expression of Bcl-2 (Qi et al., 2000) and in human pediatric rhabdoid tumor G401 cells, this molecule activates the antiapoptotic pathway mediated by the Janus-activated kinases (JAKs) and STAT1 (Ratovitski et al., 1998) . Midkine has been also shown to activate the survival pathway mediated by Akt in cultured neurons as a putative mechanism for its neuroprotection (Owada et al., 1999) . The differential expression of midkine between drug-resistant and -sensitive cells (Figure 2a) indicates that this cytokine may play a role in drug resistance as well. Quantitative RT-PCR ( Figure 2b ) and Western blot analysis using CM derived from drug-resistant and -sensitive cells (Figure 2c ) have been performed to confirm the differential expression of this molecule between the two cell types. In both cases, a highly significant increase in midkine expression was observed in the drug-resistant cells. To verify whether this finding was unique to neuroblastoma cells or can be extended to pairs of drug-sensitive and -resistant cell lines from other cancers, we tested expression of midkine in cisplatin-resistant ovarian cancer cells and doxorubicin-resistant osteosarcoma cells and found that they express higher amounts of this molecule than their drug-sensitive counterparts. Differential expression of midkine between cancer cell lines in relation to their drug-resistance status was not limited to one tumor cell type or a specific drug but rather appears to represent a generalized phenomenon associated with drug resistance.
Effect of midkine-enriched fractions from CM of drug-resistant cells on wild-type cell response to doxorubicin
Based on the knowledge that midkine is a heparinbinding protein (Muramatsu and Muramatsu, 1991) , we utilized heparin affinity chromatography to optimize the purification of this molecule. Among the two major chromatographic peaks obtained (Figure 3a) , peak I appears to contain higher molecular weight heparin-binding proteins as opposed to peak II which may contain midkine and other low molecular weigh heparin-binding proteins. Area under the curve of peak II from equal volumes of CM/W and CM/R, harvested from cultures which were 80-90% confluent, was approximately three times greater for CM/R than CM/W. Western blot analysis of midkine expression in peaks I and II from both cell types revealed that this protein was present only in peak II of CM from drugresistant cells (Figure 3b ). Midkine-enriched chromatographic fractions utilizing its heparin-binding properties were obtained to further confirm the differential expression of this molecule between drug-resistant andsensitive cells and also to determine whether these fractions exert any cytoprotective function against doxorubicin. A number of collected fractions from the column were tested in a single blind manner for their ability to alter doxorubicin toxicity in SKN-SH cells. Equal amounts of proteins (40 mg/ml) were incubated with the cells in CM in the presence of doxorubicin for 48 h. The data shown in Figure 4a indicated that fraction 3 and 4 were clearly distinguishable from others in reducing doxorubicin-induced cell death. These two fractions were derived from peak II obtained by chromatography of conditioned medium (CM) from drug-resistant cells. Fractions derived from peak I of this same medium, or from peaks I and II from CM from wild-type cells, were less effective in protecting the cells against doxorubicin. This suggests that the protective action correlated with expression of midkine and that the active principle in CM from drug-resistant cells could likely be narrowed down to a heparinbinding fraction enriched in midkine.
The effect of midkine-enriched fractions on activation of Stat3 and Akt in SKN-SH cells was determined by Western blot. Cells were treated with these fractions (40 mg/ml) for 15 min, and equal amounts of proteins were resolved by SDS-PAGE and probed with specific antibodies to Stat3, phospho-Stat3 (P-Stat3), Akt and phospho-Akt (P-Akt). As shown in Figure 4b , Stat3 was not activated by midkine-enriched fraction, however, Akt was strongly phosphorylated. The lack of Stat3 activation under these circumstances was somewhat surprising since we had shown that CM from drugresistant cells activates both Stat3 and Akt in the drugsensitve cells (Emran et al., 2002) . It appears from these findings that separate factors are responsible for the activation of Stat3 and Akt by CM from doxorubicinresistant cells, and that only molecules that activate Akt, such as midkine, could exert a significant protective effect against doxorubicin toxicity.
Transfection of drug-sensitive cells with the midkine gene has a protective effect against doxorubicin toxicity An expression vector containing the midkine gene was introduced successfully in Saos-2 and SKN-SH cells and after selection with G418, the transfected cells were found to express midkine in a manner that was almost equivalent to that of doxorubicin-resistant cells ( Figure 5a , b and Supplemental material). Cytoprotection against doxorubicin conferred by midkine transfection was determined after cells were subjected to treatment with doxorubicin for 48 h followed by determination of cell viability using the MTT assay (Figure 5c and d). These data indicated that midkinetransfected wild-type cells acquired a significant level of drug resistance as compared to their nontransfected parental cells. The findings provide a further argument that midkine was able to protect drug-sensitive cells from drug toxicity and induce drug resistance. In the context of this study, midkine may be also considered as a molecular mediator for the intercellular transfer of drug resistance.
Putative mechanisms underlying the cytoprotective action of midkine
The signaling pathways most likely to mediate midkine's action were investigated in the transfected cells. Emphasis of these experiments focused on midkine's effect on doxorubicin-induced proliferation arrest and apoptosis. We have shown previously that depending on the drug concentration, doxorubicin induced irreversible growth arrest (also called senescence) followed by apoptosis (Rebbaa et al., 2003) . In the present study, midkine-transfected Saos-2 cells were subjected to treatment with either senescence or apoptosis-inducing drug concentrations and the expression of survival, apoptotic and senescence markers was compared in transfected and nontransfected cells. As shown in Figure 6 , activation of the survival molecule Stat3 did not differ significantly between the two cell lines, nor did the effects of doxorubicin on this molecule. However, Akt was constitutively active in the midkinetransfected cells although its activation level was not affected significantly by doxorubicin in both transfected and nontransfected cells. Similarly, other members of the survival pathway mediated by Akt namely mTOR and Bad were also activated in the midkine-transfected cells (Figure 6 ). These findings confirmed the selective effect of enriched-midkine fraction on activation of Akt and not Stat3 (shown in Figure 4 ) and suggest that activation of the Akt pathway occurred in response to ) and since senescence occurs earlier than apoptosis in terms of stress level (Chang et al., 2002; Rebbaa et al., 2003; Shay and Roninson, 2004) , not only apoptosis but also senescence must be inhibited in order for cancer cells to become resistant. In this context, we have tested whether inhibition of senescence could be part of midkine's function. For this purpose, expression of the cell cycle inhibitor p21/WAF1 (overexpression of which forces cells into senescence) was compared in midkinetransfected and nontransfected cells, particularly when exposed to various concentrations of doxorubicin. Data presented in Figure 7a indicate that the expression of p21/WAF1 was significantly reduced in midkine-transfected cells to a level equivalent to that of drug-resistant cells. More importantly, doxorubicin-induced overexpression of p21/WAF1 was also strongly inhibited in the midkine-transfected cells. The effect of midkine did not appear to be mediated by its ability to induce cellular proliferation since incubation of wild-type cells with CM from midkine-transfected cells had no effect on cellular proliferation (Figure 7, panel b) . This suggested that midkine exert a cytoprotective and not a pro-proliferative function at least in this cellular model. To further confirm these findings, we have subjected midkinetransfected and nontransfected Saos2 cells to treatment with doxorubicin and compared their response to that of the doxorubicin resistant cells (Figure 7c ). The data indicate that in the absence of drug, the three cell line have comparative proliferation rates over a period of 5 days. However, treatment of the wild-type cells with 10 À7 M doxodubicin resulted in total blockage of their growth while the doxorubicin resistant cells continued to grow at a normal rate. Interestingly, although proliferation of the midkine-transfected cells was relatively slowed down (Figure 7c) , it was not completely inhibited suggesting that this molecule may indeed protect cancer cells from drug toxicity. Additional confirmation of this effect is brought by flow cytometry analysis (Figure 8 ), and exposure of nontransfected wild-type cells to 10 À7 M doxorubicin for 24 h strongly induced G2 arrest and inhibited the S phase of cell cycle in the wild-type cells. These effects were attenuated (particularly inhibition of the S phase) in the midkine-transfected cells and the Figure 6 Effect of midkine on survival and death pathways. Midkine-transfected (W-MK) and nontransfected (WT) Saos2 cells were treated with doxorubicin at the indicated concentrations for 24 h and expression of Phospho-Stat3 (P-Stat3), Phospho-Akt (P-Akt) phospho-mTOR (P-mTOR), phospho-Bad (P-Bad) and cleaved caspase-3 (Cl. Casp-3) were determined by Western blot using specific antibodies. Anti-b-Actin was used as loading marker 
Discussion
This investigation addressed the possibility that an intercellular crosstalk may occur in drug-resistant tumors, particularly between cells that have acquired the drug resistance phenotype and neighboring drugsensitive partners. Communication between these cells could be achieved by secretion of survival factors, such as midkine, from resistant cells to protect the surrounding cellular environment and enabling survival of the tumor as a whole. While inhibition of apoptosis represents a logical mechanism for this protection as shown in Figures 1 and 6 , the suppression of senescence may be required as well (Figures 7 and 8 ).
Midkine is a growth factor first discovered as mediator of retinoic acid-induced differentiation (Muramatsu, 1993) . Further studies revealed that this molecule was able to exert a survival function in a variety of cellular systems (Muramatsu, 2002; Stoica et al., 2002; Sakaguchi et al., 2003) and against various stimuli, suggesting that it could be associated with drug resistance (Kang et al., 2004) . Overexpression of midkine in drugresistant cell lines as shown in Figure 2 confirmed this assumption and suggested that it may play a role as a cytoprotective signal between drug-resistant andsensitive cells. As a preliminary approach to evaluate the function of this molecule, we took advantage of its heparin-binding function and obtained enriched fractions of CM from drug-resistant cells (Figure 3a) . Only the fractions that contain midkine ( Figure 3b) were found to have a protective effect against doxorubicin toxicity in drug-sensitive cells (Figure 4a ). In agreement with this, midkine-enriched fractions were able to activate the survival pathway mediated by Akt in these cells (Figure 4b ). However, since these chromatographic fractions may also contain other growth and/or survival factors with heparin-binding properties, there is the Figure 8 Flow cytometry analysis of the cytoprotective action of midkine. Cells were subjected to treatment with doxorubicin as described in Figure 7 and after 2 days of incubation they were fixed, stained with propidium iodide and subjected to flow cytometry analysis possibility that they can also contribute to the observed effect. To verify or to rule out this possibility, we have transfected the midkine gene in drug-sensitive cells and evaluated its effect on cellular responsiveness to doxorubicin. Our data indicate that this intervention not only conferred a drug resistance phenotype to the engineered cells ( Figure 5 ) but also appeared to act by activating the Akt pathway and inhibiting thereby two major cellular responses to cytotoxic agents: senescence and apoptosis (Figures 6, 7 and 8) .
Overall, evidence presented in this study constitutes a proof of principle to support the existence of an intercellular cytoprotective signaling within drug-resistant tumors. Midkine appeared to be the primary candidate implicated in this process; however, there are perhaps many other survival factors potentially secreted by drug-resistant cells under these circumstances that may participate to the same end result as well. Along these lines, although we have demonstrated that midkine was differentially expressed in three different pairs of neoplastic cell types, caution must be taken about the generalization of this phenomenon. Validation of this concept will require not only that survival factors are secreted from drug-resistant cells, but that the neighboring drug-sensitive cells must express the receptor for the secreted cytoprotective factor as well as the related signaling pathway. By virtue of its apparent lack of specificity, midkine may bind nonspecifically to and activate various receptors such as integrins, proteoglycans, or low-density lipoproteins, leading to activation of more than one survival pathway and thus increasing its chances to mediate cytoprotection.
While the role of apoptosis in cell survival and development of drug resistance is well described, the implication of senescence in these phenomena is not well understood. Since drug-resistant cells must not only be alive but able to proliferate, a survival molecule such as midkine must not only inhibit apoptosis but also senescence in order to initiate drug resistance. The finding that midkine inhibit p21/WAF1 expression is novel and warrant more research towards investigating the underlying mechanism. Further studies are also needed to understand how cytotoxic drugs such doxorubicin induce midkine expression and the temporal occurrence of this in the context of drug resistance development.
Materials and methods
Reagents
All materials utilized in this study were purchased from the following companies: Dulbecco's modified Eagle's medium (DMEM) (Mediatech, Inc., Pittsburgh, PA, USA); fetal bovine serum (FBS) (Hyclone, Logan, UT, USA); doxorubicin; 3-(4,5-dimethyl-2-thiazolyl)2,5-diphenyl tetrazolium bromide (MTT) (Sigma, St Louis, MO, USA); antibodies to midkine (Santa Cruz Biotechnologies, CA, USA); antibodies to phosphor-Akt, phosphor-Bad and phospho-mTOR (Cell Signaling Technologies, Beverley, MA, USA); secondary antibodies conjugated to horseradish peroxidase (Promega Corporation, Madison, WI, USA); enhanced chemiluminescence reagents (Supersignal) (Pierce Corp., Rockford, IL, USA); Immobilon-P transfer membrane for Western blot (Millipore, Bedford, MA, USA); and the cytokine cDNA array was purchased from R&D Systems (Minneapolis, MN, USA).
Cell culture and generation of doxorubicin-resistant cell lines
Human neuroblastoma (SKN-SH) and osteosarcoma (Saos2) cells were obtained from the American Type Culture Collection (SKNS-H-ATTC# HTB-11; Saos2-ATTC# HTB-85) and grown in DMEM supplemented with 10% FBS at 371C in a 95% air/5% CO 2 atmosphere. The generation of doxorubicinresistant SKN-SH/R and Saos-2/R cells was achieved by incubating parental cell lines with incremental concentrations of DOX ranging from 10 À8 to 10 À6 M over a period of 3 months. Cells were deemed to be drug resistant to 10 À6 M DOX after surviving at least 3 three consecutive passages at this drug concentration following which they were continuously selected in DMEM containing this agent.
Collection of CM
Near confluent cultures of SKN-SH and SKN-SH/R cells grown in 25 cm 2 tissue culture flasks containing DMEM and 10% FBS at 371C in 95% air/5% CO 2 were used for this purpose. CM was replaced with DMEM containing 0% FBS, 48 h prior to collection of CM under sterile conditions. Specimens were stored at À201C until chromatographic analysis and purification performed.
Cytoprotection assay
Cells were incubated with doxorubicin at concentrations varying between 1 Â 10 À9 to 1 Â 10 À5 M for 96 h. Viable cells were quantitatively estimated by a colorimetric assay utilizing MTT, as described previously (Rebbaa et al., 2001) . MTT (10 ml of 5 mg/ml solution) was added to each well of the titration plate and incubated for 4 h at 371C. The cells were then solubilized by the addition of 100 ml of 10% SDS/0.01 M HCl and incubated for 15 h at 371C. The optical density of each well was determined in an ELISA plate reader using an activation wavelength of 570 nm and reference wavelength of 650 nm. The percentage of viable cells was determined by comparison with untreated control cells.
Human cytokine cDNA array analysis
Total RNA was extracted from SKN-SH and SKN-SH/R cells using the Tri-reagent protocol (Sigma, St Louis, MO, USA). Cells from 25 cm 2 flasks were washed twice with 5 ml phosphate-buffered saline (PBS) and placed into 1 ml of lysis buffer. Following incubation at room temperature for 5 min, 200 ml of chloroform was added, and 15 min thereafter, the mixture centrifuged at 12 000 g for 15 min at 41C. The upper phase containing RNA was transferred and precipitated by addition of isopropanol (500 ml). The pellet was washed with 1 ml of ethanol (75%), dried and resuspended in 30 ml of TE buffer.
The integrity of sample RNA and genomic DNA contamination was assessed by agarose gel electrophoresis. Generation of radiolabeled cDNA was performed as follows: 4 ml of human cytokine-specific primers provided in the kit were annealed with 2 mg of RNA in a final volume of 15 ml. This mixture was incubated for 2 min at 901C, and for 20 min at 421C. The reverse transcription reaction mixture contained the annealed RNA-primers plus 6 ml of 5 Â reverse transcriptase buffer, 1 ml of 10 mM dATP, dGTP, dTTP, 0.5 ml of 100 mM dCTP, 0.5 ml of 40 U/ml RNasin, 2 ml of [ 32 P]d-CTP (2000-3000 Ci/mmol), 2 ml of 25 U AMV reverse transcriptase and 1 ml of distilled water. After incubation for 2 h at 421C, unincorporated radioactivity was removed by passing the solution through a Sephadex G-25 spin column.
Prior to the hybridization reaction, the cDNA array membrane was prehybridized with denatured Salmon testes DNA by incubating the membrane with 5 ml of prehybridization solution for 1 h at 651C. Radiolabeled cDNA was then hybridized with the cDNA array membrane in 3 ml of hybridization solution for 15 h at 651C. The membrane was washed three times with 40 ml of wash solution provided in the kit, air-dried for 5 min, and an autoradiogram prepared.
Heparin affinity column chromatography
A slight modification of a previously described procedure (Ratovitski et al., 1998) was utilized. CM was prefiltered under vacuum using a Millipore filter with a pore size of 0.1 mm to remove any residual protein. A HiTrap Heparin Column (Amersham/Pharmacia) and discontinuous gradient system was used for the chromatographic analysis of CM. The heparin affinity column was equilibrated with a 20 mM TrisHCl buffer (pH 7.5) containing 0.2 M NaCl. CM was then passed over the column and washed with 20 mM Tris-HCl buffer containing 0.5 M NaCl. The elution of proteins from the column was performed with a 20 mM Tris-HCl buffer containing 1.5 M NaCl and the eluate scanned in a flow spectrophotometer. Fractions of 0.25 or 1.0 ml were collected using an automated fraction collector.
Western blot analysis
Cell lysates, CM or chromatographic fractions eluted from the heparin affinity column were solubilized in electrophoresis loading buffer (SDS þ b-mercapto-ethanol) and 50 mg of protein was applied to pre-cast (4-20% gradient) SDSpolyacrylamide gels (Gradipore, Inc.) for electrophoresis. Proteins were then transferred by electroblot to a nitrocellulose membrane (BioRad, Inc.) and probed with polyclonal antibodies against midkine (Santa Cruz Biotechnology, Inc.) after blocking with 1% albumin, 0.05% Tween 20 in PBS. To assess the effect of midkine on expression of Stat3, Akt, Caspase-3 and p21/WAF1 expression, membranes were probed with specific antibodies to these molecules. After incubation with the corresponding secondary antibodies conjugated to horseradish peroxidase (Promega Corp.), reactive bands were detected by enhanced chemiluminescence (Pierce Corp.).
Construction of human midkine expression plasmid and cell transfection
A 444-bp SacII-XhoI human Midkine (hMK) cDNA fragment was synthesized by GeneScript Corp. based on the complete 432-bp human midkine gene cDNA sequence (genebank D10604). The following modifications were performed: the C base at 57 was mutated into A to eliminate the endogenous SacII restriction site without any amino-acid change, the CCGCGG sequence was added to the 5 0 end to generate a SacII restriction site and the CTCGAG sequence was added to the 3 0 end to create a XhoI restriction site. The 12 kb plasmid Pco11-EGFR-neo, which contained a murine retroviral-based shuttle vector and a selectable genetic marker (neo R ) was kindly provided by Dr Jeffrey DeClue (Natl. Cancer Inst.). In order to generate the Pco11-hMK-neo plasmid, a 4.2 kb SacIIXhoI EGFR cDNA fragment was removed and replaced by a 444-bp SacII-XhoI Human Midkine (hMK) fragment.
Stable transfectants were produced using Saos-2 or SKN-SH cells maintained in DMEM medium supplemented with 10% fetal calf serum (FCS) in 24-well plates. The Pco11-hMKneo plasmid was introduced using LipofectAMINE Reagent 2000 following the manufacturer's protocol (Invitrogen). After 48 h, cells were incubated in the presence of G418 (1 mg/ml) and selected for 2 weeks. Determination of midkine expression was performed by harvesting and concentrating CM (about 10 times), followed by Western blot using specific antibody to this molecule.
Effect of CM from midkine-transfected cells on proliferation of their wild-type counterparts CM from midkine-transfected cells was collected as described above and its effect on proliferation of nontransfected cells was measured using a method described previously (Li et al., 2004) . Briefly, 5000 cells/well were seeded in 48-well plates in DMEM containing 10% FBS and after 3 days of incubation, media was replaced with CM from midkine-transfected cells and incubated for additional 24 h. Media in all wells were replaced with fresh regular DMEM and cell number counted for subsequent days using a hemocytometer on days 4, 5, 7 and 8.
Flow cytometry
Nontransfected, midkine-transfected and doxorubicin-resistant SKN-SH cells (about 10 6 ) were incubated with doxorubicin (10 À7 M) for 48 h, then collected by trypsinization and washed twice with PBS containing 5 mM EDTA. Cells were fixed in 70% ethanol and incubated for 10 min on ice. Prior to flow cytometry analysis, cells were washed twice with PBS/5 mM EDTA and subjected to treatment with RNAse A (2 mg/ml of PBS) for 30 min at 371C. The cells were then incubated with propidium iodide (10 mg/ml) for 1 h at room temperature, filtered and DNA content analysed by flow cytometry.
